CA-ALKIRA/CHECK-POINT
29.9.2021 16:12:04 CEST | Business Wire | Press release
Cloud networking pioneer Alkira® and Check Point Software Technologies (NASDAQ: CHKP), a leading provider of cyber security solutions globally, today announced a technology alliance to provide Check Point Software’s CloudGuard firewalls in Alkira’s Cloud Network infrastructure as-a-Service (CNaaS). This comes as organizations deploying application workloads to the cloud are struggling with the complexity of implementing consistent enterprise-wide security controls spanning cloud, multi-cloud and on-premises environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005357/en/
The Check Point CloudGuard platform provides cloud native security with advanced threat prevention for all assets and workloads enabling customers to deploy the same robust security in the cloud that they are used to with on-premises systems. Alkira brings a high-performance cloud network-as-a-service with global virtual infrastructure, advanced routing, intelligent service insertion and dynamic auto-scale, simplifying set-up and day 2 operations for enterprise cloud networking and security deployments.
Atif Khan, CTO and Founder of Alkira, said:
“Alkira and Check Point simplify security deployments and make it easier for enterprise customers to apply a single security posture across the entire enterprise network spanning cloud, multi-cloud and existing data center or colocation facilities. Delivering the Alkira virtual network infrastructure and Check Point security management tools as a service allows enterprises to avoid the costs and complexity of DIY solutions, and provides guaranteed performance and scalability.”
TJ Gonen, Head of Cloud Security at Check Point added
:
“The combination of Check Point CloudGuard and Alkira simplifies the process of provisioning and ongoing management in the cloud networking environment which is a big win for enterprise customers. The Check Point CloudGuard platform provides cloud native security with advanced threat prevention for all assets and workloads, across public, hybrid and multi-cloud environments, enabling customers to benefit from a single unified security platform.”
Alkira Cloud Services Exchange® (CSX) fully automates the provisioning, licensing, service insertion, scaling and health monitoring of CloudGuard network security gateways. Alkira seamlessly inserts the CloudGuard gateways at any point in the Alkira global cloud backbone, providing stateful security controls for any on-premises, cloud, and Internet application traffic. Alkira allows customers to decouple CloudGuard from the specific cloud providers, thus providing a more efficient multi-cloud security architecture.
Cloud environments offer global presence and vast compute resources but lack the necessary routing, policy and operational controls enterprises require for a streamlined cloud firewall deployment. Even in a single cloud environment, do-it-yourself solutions result in a complex sprawl of virtual machine instances and traffic management scenarios. They also tend to make inefficient use of resources. All these problems are made worse in multi-cloud environments.
Check Point CloudGuard can be rapidly provisioned into one or multiple globally distributed Alkira Cloud Exchange Points (CXP) to provide security policy enforcement for application traffic between any set of endpoints connected to the Alkira global cloud backbone. Once CloudGuard has been provisioned within an Alkira CXP it can provide:
- Security policy to and between public clouds
- Cloud hosted, stateful firewall services for branches and data centers
- Regionalized Internet breakouts for secure SaaS application access
- Cloud DMZ environment for Internet facing applications
- Shared cloud application services for partners and M&As
Alkira’s visual policy manager simplifies policy configuration, scoping and inspection, and streamlines auditing for assurance and compliance purposes. Alkira’s intent-based approach selectively routes traffic to firewalls according to need, improving efficiency of firewall utilization and optimizing network performance. Customers have a choice of bring-your-own license (BYOL) or pay-as-you-go (PAYG) licensing models.
Check Point offers a multilevel security architecture that defends enterprises’ cloud, network and mobile device-held information, and a comprehensive and intuitive one-point-of-control security management system.
CloudGuard is available in the Alkira network services marketplace.
For more information:
- Download the Alkira and Check Point solution brief .
- Join the Alkira and Checkpoint webinar October 13
About Alkira
Alkira® delivers Cloud Networking as-a-Service (CNaaS) and developed the first Network Cloud which enables enterprises to build and deploy a secure global unified multi-cloud network infrastructure as-a-service that delivers network connectivity, advanced network and security services, and end-to-end visibility and governance. Alkira Cloud Services Exchange® (CSX) seamlessly and securely connects branches, data centers, remote users and clouds. Alkira CSX is available on the AWS and Azure Marketplaces. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP and founding team member at Viptela. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.Alkira.com or follow us @AlkiraNet
Alkira® , Alkira Cloud Services Exchange® and Alkira Cloud Exchange Point® are registered trademarks of Alkira, Inc. All other marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005357/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
